More than half of individuals admitted to an emergency department, or ED, for drug-induced nonallergic angioedema — with nearly all of these patients experiencing swelling as a side effect of medications known as angiotensin-converting enzyme inhibitors, or ACEIs — showed improvement, with most staying briefly and few returning…
Sebetralstat, an oral small molecule being developed by Kalvista Pharmaceuticals, provided adults and adolescents with hereditary angioedema (HAE) with early on-demand treatment for swelling attacks and offered fast symptom relief, even when swelling affected the larynx (voice box). That’s according to interim data from KONFIDENT-S (NCT05505916),…
An assay that measures C1 inhibitor (C1-INH) activity on a dried blood spot after a blood sample is blotted onto a piece of filter paper appears to work as well as a standard, color-based assay to diagnose hereditary angioedema (HAE) and is easier to handle, a study found. Dried…
Pharvaris plans a trial of deucrictibant to treat acquired angioedema this year, following promising data showing the experimental oral small molecule helped to stop or prevent swelling attacks in three patients. The company has been testing deucrictibant in a pair of Phase 3 trials, CHAPTER-3 (NCT06669754)…
Garadacimab appears to be safe for long-term use as prophylaxis, or preventive treatment, reducing the frequency of swelling attacks in adults and adolescents with hereditary angioedema (HAE), according to an interim analysis of data from an ongoing Phase 3 extension study sponsored by its developer, CSL…
Many people with hereditary angioedema (HAE) delay on-demand treatment for their attacks because they think the swelling isn’t severe enough or due to high costs and challenges related to injection, which can worsen symptoms, a survey study finds. “Survey results highlight that decision making regarding on-demand treatment in HAE…
People with hereditary angioedema (HAE) who have normal C1-inhibitor (C1-INH) levels and activity appear to have more active disease and more severe symptoms than those with HAE type 1 or 2, a real-world study found. These patients also “experience greater impairment to their quality of life, work, and daily functioning,”…
Transitioning from other prophylactic, or preventive, treatments, to Orladeyo (berotralstat) or Takhzyro (lanadelumab) can take some time and adjustment, but helps to safely prevent swelling episodes in hereditary angioedema (HAE) patients. That’s according to a study reporting the process of such a treatment transition for four family members…
Switching to Orladeyo (berotralstat) may help reduce the frequency and duration of swelling attacks in people with hereditary angioedema (HAE) who have normal levels and activity of a protein called C1-inhibitor, according to a European case series. These data add “clinically relevant evidence” to a growing body of…
An immediate-release capsule of deucrictibant that’s being developed by Pharvaris continues to show promise as an on-demand and preventive treatment for attacks of hereditary angioedema (HAE). “We believe deucrictibant is the only oral molecule with the potential to address both the on-demand and prophylactic treatment modalities for people…
Get regular updates to your inbox.
